The Association Between the Occurrence of Common Treatment-Emergent Adverse Events and Efficacy Outcomes After Lasmiditan Treatment of a Single Migraine Attack

Erin G. Doty¹, Paula M. Hauck¹, John H. Kuge¹, Mika Komori¹, Ann M. Hake¹², Yan Dong¹, Richard B. Lipton³

¹ Eli Lilly and Company, Indianapolis, IN, USA.
² Indiana University School of Medicine, Indianapolis, IN, USA.
³ Albert Einstein School of Medicine, The Bronx, NY, USA.

CNS Drugs

Short title: TEAEs and efficacy of LTN

Key words: lasmiditan, migraine, treatment-emergent adverse events, pain freedom, efficacy, efficacy-TEAE association

Corresponding author:

Erin G. Doty, MD
Lilly Technology Center South, Indianapolis IN 46221 U.S.A.
doty_erin_gautier@lilly.com
+1 (317)517-4018 (mobile)
**Supplemental Table 1.** Additional demographic breakdown by country

| Country*                  | Placebo (N=1976) | L50 mg (N=742) | L100 mg (N=1958) | L200 mg (N=1926) |
|---------------------------|------------------|----------------|------------------|------------------|
| Austria n (%)             | 3 (0.2)          | 0 (0.0)        | 5 (0.3)          | 3 (0.2)          |
| Belgium n (%)             | 9 (0.5)          | 0 (0.0)        | 9 (0.5)          | 10 (0.5)         |
| Switzerland n (%)         | 7 (0.4)          | 0 (0.0)        | 5 (0.3)          | 7 (0.4)          |
| China n (%)               | 47 (2.4)         | 0 (0.0)        | 45 (2.3)         | 44 (2.3)         |
| Czech Republic n (%)      | 31 (1.6)         | 0 (0.0)        | 33 (1.7)         | 32 (1.7)         |
| Germany n (%)             | 155 (7.8)        | 68 (9.2)       | 153 (7.8)        | 154 (8.0)        |
| Denmark n (%)             | 11 (0.6)         | 0 (0.0)        | 9 (0.5)          | 10 (0.5)         |
| Spain n (%)               | 22 (1.1)         | 0 (0.0)        | 18 (0.9)         | 21 (1.1)         |
| France n (%)              | 8 (0.4)          | 0 (0.0)        | 7 (0.4)          | 7 (0.4)          |
| United Kingdom n (%)      | 209 (10.6)       | 44 (5.9)       | 207 (10.6)       | 204 (10.6)       |
| Hungary n (%)             | 5 (0.3)          | 0 (0.0)        | 6 (0.3)          | 6 (0.3)          |
| India n (%)               | 13 (0.7)         | 0 (0.0)        | 12 (0.6)         | 14 (0.7)         |
| Italy n (%)               | 8 (0.4)          | 0 (0.0)        | 7 (0.4)          | 7 (0.4)          |
| Japan n (%)               | 214 (10.8)       | 88 (11.9)      | 208 (10.6)       | 182 (9.4)        |
| Mexico n (%)              | 34 (1.7)         | 0 (0.0)        | 29 (1.5)         | 32 (1.7)         |
| Netherlands n (%)         | 3 (0.2)          | 0 (0.0)        | 3 (0.2)          | 4 (0.2)          |
| Russian Federation n (%)  | 13 (0.7)         | 0 (0.0)        | 13 (0.7)         | 12 (0.6)         |
| United States n (%)       | 1184 (59.9)      | 542 (73.0)     | 1189 (60.7)      | 1177 (61.1)      |

* The denominator = the number of participants with non-missing data and therefore may be slightly different than the N shown.

Notes: Pooled data from SAMURAI, SPARTAN, MONONOFU, and the first treated attack from CENTURION were used in the analysis.

Abbreviations: L = lasmiditan; N = number of participants in the analysis population; n = number of subjects within each specific category
**Supplemental Table 2.** Proportions of participants experiencing CTEAEs by 48 hours based on 2-hour pain outcome

| Participants with | Placebo N=1745 | Odds Ratio (95% CI) vs. M/S | L50 mg N=673 | Odds Ratio (95% CI) vs. M/S | L100 mg N=1719 | Odds Ratio (95% CI) vs. M/S | L200 mg N=1698 | Odds Ratio (95% CI) vs. M/S |
|------------------|----------------|-----------------------------|-------------|-----------------------------|---------------|-----------------------------|---------------|-----------------------------|
| ≥1 CTEAE         |                |                             |             |                             |               |                             |               |                             |
| M/S              | 782 71 (9.1)   |                             | 204 41 (20.1)|                             | 417 109 (26.1)|                             | 404 116 (28.7)|                             |
| IMP              | 496 59 (11.9)  | 1.3 (0.9, 1.9)              | 203 48 (23.6)| 1.2 (0.7, 1.9)              | 574 226 (39.4)| 1.7 (1.2, 2.2)***            | 473 233 (49.3)| 2.2 (1.7, 3.0)***            |
| PF               | 270 21 (7.8)   | 0.9 (0.5, 1.5)              | 184 51 (27.7)| 1.6 (1.0, 2.5)              | 498 205 (41.2)| 2.0 (1.5, 2.7)***            | 575 277 (48.2)| 2.4 (1.8, 3.1)***            |
| Dizziness        |                |                             |             |                             |               |                             |               |                             |
| M/S              | 782 29 (3.7)   |                             | 204 15 (7.4) |                             | 417 50 (12.0) |                             | 404 63 (15.6) |                             |
| IMP              | 496 21 (4.2)   | 1.1 (0.6, 2.0)              | 203 24 (11.8)| 1.6 (0.8, 3.3)              | 574 144 (25.1)| 2.2 (1.6, 3.2)***            | 473 140 (29.6)| 2.1 (1.5, 2.9)***            |
| PF               | 270 5 (1.9)    | 0.6 (0.2, 1.5)              | 184 29 (15.8)| 2.4 (1.2, 4.5)**            | 498 126 (25.3)| 2.4 (1.7, 3.5)***            | 575 149 (25.9)| 1.8 (1.3, 2.6)***            |
| Somnolence       |                |                             |             |                             |               |                             |               |                             |
| M/S              | 782 11 (1.4)   |                             | 204 10 (4.9) |                             | 417 19 (4.6)  |                             | 404 15 (3.7)  |                             |
| IMP              | 496 19 (3.8)   | 2.7 (1.3, 5.7)**            | 203 11 (5.4) | 1.0 (0.4, 2.5)              | 574 41 (7.1)  | 1.3 (0.7, 2.3)               | 473 40 (8.5)  | 1.9 (1.0, 3.6)*              |
| PF               | 270 10 (3.7)   | 2.5 (1.0, 6.1)*             | 184 15 (8.2) | 1.8 (0.8, 4.0)              | 498 43 (8.6)  | 1.8 (1.0, 3.2)*              | 575 67 (11.7) | 3.3 (1.8, 5.9)***            |
| Paresthesia      |                |                             |             |                             |               |                             |               |                             |
| M/S              | 782 11 (1.4)   |                             | 204 3 (1.5)  |                             | 417 19 (4.6)  |                             | 404 26 (6.4)  |                             |
| IMP              | 496 12 (2.4)   | 1.8 (0.8, 4.2)              | 203 6 (3.0)  | 2.1 (0.5, 8.8)              | 574 39 (6.8)  | 1.6 (0.9, 2.9)               | 473 52 (11.0) | 1.9 (1.2, 3.1)*              |
| PF               | 270 4 (1.5)    | 1.2 (0.4, 4.0)              | 184 7 (3.8)  | 2.6 (0.7, 10.2)             | 498 34 (6.8)  | 1.7 (0.9, 3.0)               | 575 58 (10.1) | 1.8 (1.1, 2.9)*              |
| Nausea           |                |                             |             |                             |               |                             |               |                             |
| M/S              | 782 22 (2.8)   |                             | 204 11 (5.4) |                             | 417 27 (6.5)  |                             | 404 20 (5.0)  |                             |
| IMP              | 496 11 (2.2)   | 0.7 (0.4, 1.5)              | 203 5 (2.5)  | 0.4 (0.1, 1.2)              | 574 17 (3.0)  | 0.4 (0.2, 0.8)**             | 473 28 (5.9)  | 1.1 (0.6, 1.9)               |
| PF               | 270 3 (1.1)    | 0.4 (0.1, 1.6)              | 184 4 (2.2)  | 0.4 (0.1, 1.2)              | 498 19 (3.8)  | 0.6 (0.3, 1.1)               | 575 33 (5.7)  | 1.2 (0.7, 2.2)               |
| Fatigue          |                |                             |             |                             |               |                             |               |                             |
| M/S              | 782 7 (0.9)    |                             | 204 6 (2.9)  |                             | 417 17 (4.1)  |                             | 404 16 (4.0)  |                             |
| IMP              | 496 3 (0.6)    | 0.7 (0.2, 2.6)              | 203 5 (2.5)  | 0.9 (0.3, 2.9)              | 574 32 (5.6)  | 1.4 (0.8, 2.6)               | 473 29 (6.1)  | 1.5 (0.8, 2.9)               |
| PF               | 270 0 (0.0)    | 0.0 (-,-)                   | 184 5 (2.7)  | 0.9 (0.3, 3.1)              | 498 26 (5.2)  | 1.4 (0.7, 2.6)               | 575 41 (7.1)  | 2.0 (1.1, 3.7)*              |

* p<0.05, ** p<0.01, *** p<0.001
Abbreviations: CI = confidence interval; CTEAE = common treatment-emergent adverse event; h = hour; IMP = improved to mild; L = lasmiditan; M/S = continued moderate/severe; N = number of participants in the analysis population; N’ = number of participants experiencing the pain category; n = number of participants experiencing the pain category and treatment-emergent adverse event; PF = pain freedom
Supplemental Table 3. Proportion of participants experiencing CTEAEs by 48 hours based on 2-hour disability freedom

| Participants with ≥1 CTEAE | Placebo N=1760 | L50 mg N=679 | L100 mg N=1742 | L200 mg N=1708 |
|-----------------------------|----------------|--------------|-----------------|-----------------|
|                             | N' | n (%)  | Odds Ratio (95% CI) | N' | n (%)  | Odds Ratio (95% CI) | N' | n (%)  | Odds Ratio (95% CI) | N' | n (%)  | Odds Ratio (95% CI) |
| **Dizziness**               |    |        |                    |    |        |                    |    |        |                    |    |        |                    |
| DF                          | 333 | 24 (7.2) | 0.7 (0.5, 1.2) | 205 | 46 (22.4) | 1.0 (0.7, 1.5) | 493 | 161 (32.7) | 0.9 (0.7, 1.2) | 511 | 217 (42.5) | 1.1 (0.9, 1.4) |
| No DF                       | 1259 | 129 (10.2) |            | 412 | 96 (23.3) |            | 1076 | 407 (37.8) |            | 1002 | 433 (43.2) |            |
| **Somnolence**              |    |        |                    |    |        |                    |    |        |                    |    |        |                    |
| DF                          | 333 | 6 (1.8) | 0.5 (0.2, 1.2) | 205 | 27 (13.2) | 1.5 (0.9, 2.4) | 493 | 96 (19.5) | 1.0 (0.7, 1.3) | 511 | 116 (22.7) | 1.0 (0.8, 1.3) |
| No DF                       | 1259 | 50 (4.0) |            | 412 | 41 (10.0) |            | 1076 | 237 (22.0) |            | 1002 | 250 (25.0) |            |
| **Paresthesia**             |    |        |                    |    |        |                    |    |        |                    |    |        |                    |
| DF                          | 333 | 10 (3.0) | 1.1 (0.5, 2.4) | 205 | 14 (6.8) | 1.2 (0.6, 2.4) | 493 | 34 (6.9) | 1.1 (0.7, 1.7) | 511 | 53 (10.4) | 1.7 (1.1, 2.4)* |
| No DF                       | 1259 | 30 (2.4) |            | 412 | 24 (5.8) |            | 1076 | 74 (6.9) |            | 1002 | 74 (7.4) |            |
| **Nausea**                  |    |        |                    |    |        |                    |    |        |                    |    |        |                    |
| DF                          | 333 | 3 (0.9) | 0.7 (0.2, 1.9) | 205 | 7 (3.4) | 1.4 (0.5, 3.7) | 493 | 26 (5.3) | 0.8 (0.5, 1.3) | 511 | 53 (10.4) | 1.3 (0.9, 1.9) |
| No DF                       | 1259 | 23 (1.8) |            | 412 | 10 (2.4) |            | 1076 | 71 (6.6) |            | 1002 | 88 (8.8) |            |
| **Fatigue**                 |    |        |                    |    |        |                    |    |        |                    |    |        |                    |
| DF                          | 333 | 0 (0.0) | 0.0 (-, -) | 205 | 3 (1.5) | 0.3 (0.1, 1.2) | 493 | 8 (1.6) | 0.3 (0.2, 0.7)** | 511 | 24 (4.7) | 1.0 (0.6, 1.6) |
| No DF                       | 1259 | 10 (0.8) |            | 412 | 13 (3.2) |            | 1076 | 59 (5.5) |            | 1002 | 59 (5.9) |            |
| * p<0.05, ** p<0.01         |    |        |                    |    |        |                    |    |        |                    |    |        |                    |

Abbreviations: CI = confidence interval; CTEAE = common treatment-emergent adverse event; DF = disability freedom; L = lasmiditan; N = number of participants in the analysis population; N’ = number of participants experiencing the disability category; n = number of participants experiencing the disability category and CTEAE.
Supplemental Table 4. Proportion of participants experiencing CTEAEs by 48 hours based on 2-hour improved PGIC

| Participants with | Placebo N=1829 | L50 mg N=685 | L100 mg N=1800 | L200 mg N=1766 | Odds Ratio (95% CI) | Odds Ratio (95% CI) | Odds Ratio (95% CI) | Odds Ratio (95% CI) |
|-------------------|---------------|--------------|---------------|---------------|--------------------|--------------------|--------------------|--------------------|
| N' n (%)          | N' n (%)      | N' n (%)     | N' n (%)      | N' n (%)      |                    |                    |                    |                    |
| ≥1 CTEAE          |               |              |               |               |                    |                    |                    |                    |
| MB/VMB            | 391 38 (9.7)  | 250 58 (23.2)| 662 240 (36.3)| 667 304 (45.6) | 1.1 (0.7, 1.6)     | 1.1 (0.9, 1.3)     | 1.3 (1.0, 1.6)*    |                    |
| Other             | 1219 115 (9.4)| 372 84 (22.6)| 922 332 (36.0)| 863 353 (40.9)  |                    |                    |                    |                    |
| Dizziness         |               |              |               |               |                    |                    |                    |                    |
| MB/VMB            | 391 11 (2.8)  | 250 31 (12.4)| 662 141 (21.3)| 667 170 (25.5) | 0.8 (0.4, 1.6)     | 1.0 (0.8, 1.3)     | 1.1 (0.9, 1.4)     |                    |
| Other             | 1219 45 (3.7) | 372 37 (9.9) | 922 192 (20.8)| 863 201 (23.3) |                    |                    |                    |                    |
| Somnolence        |               |              |               |               |                    |                    |                    |                    |
| MB/VMB            | 391 18 (4.6)  | 250 17 (6.8) | 662 51 (7.7)  | 667 61 (9.1)   | 2.4 (1.2, 4.5)**   | 1.1 (0.8, 1.7)     | 1.1 (0.8, 1.7)     |                    |
| Other             | 1219 23 (1.9) | 372 21 (5.6) | 922 61 (6.6)  | 863 67 (7.8)   |                    |                    |                    |                    |
| Paresthesia       |               |              |               |               |                    |                    |                    |                    |
| MB/VMB            | 391 9 (2.3)   | 250 8 (3.2)  | 662 40 (6.0)  | 667 71 (10.6)  | 1.7 (0.7, 3.8)     | 1.1 (0.7, 1.6)     | 1.5 (1.1, 2.1)*    |                    |
| Other             | 1219 18 (1.5) | 372 9 (2.4)  | 922 57 (6.2)  | 863 71 (8.2)   |                    |                    |                    |                    |
| Nausea            |               |              |               |               |                    |                    |                    |                    |
| MB/VMB            | 391 6 (1.5)   | 250 3 (1.2)  | 662 17 (2.6)  | 667 25 (3.7)   | 0.7 (0.3, 1.8)     | 0.5 (0.3, 0.9)*    | 0.6 (0.4, 0.9)*    |                    |
| Other             | 1219 30 (2.5) | 372 17 (4.6) | 922 50 (5.4)  | 863 60 (7.0)   |                    |                    |                    |                    |
| Fatigue           |               |              |               |               |                    |                    |                    |                    |
| MB/VMB            | 391 0 (0.0)   | 250 5 (2.0)  | 662 33 (5.0)  | 667 42 (6.3)   | 0.0 (-, -)         | 0.7 (0.2, 1.9)     | 1.1 (0.7, 1.7)     |                    |
| Other             | 1219 11 (0.9) | 372 11 (3.0) | 922 47 (5.1)  | 863 47 (5.4)   |                    |                    |                    |                    |

* p<0.05, ** p<0.01

Abbreviations: CI = confidence interval; CTEAE = common treatment-emergent adverse event; L = lasmiditan; MB/VMB = much better/very much better;

N = number of participants in the analysis population; N' = number of participants experiencing the PGIC category; n = number of participants experiencing the PGIC category and CTEAE; PGIC = patient global impression of change
Supplemental Table 5. Pain freedom in participants with a CTEAE or no CTEAE

| Participants with ≥1 CTEAE | Placebo N=1745 | L50 mg N=673 | L100 mg N=1719 | L200 mg N=1698 |
|---------------------------|---------------|------------|-------------|---------------|
| N°  n (%)                 | N°  n (%)     | N°  n (%) | N°  n (%)   | N°  n (%)     |
| No                         | 1581 249 (15.7) | 523 133 (25.4) | 1111 293 (26.4) | 988 298 (30.2) |
| Yes before 2h              | 164 21 (12.8) | 150 51 (34.0) | 608 205 (33.7) | 710 277 (39.0) |
| after 2h                   | 92 13 (14.1) | 79 30 (38.0) | 445 154 (34.6) | 523 225 (43.0) |
| Dizziness                  | 1686 265 (15.7) | 600 155 (25.8) | 1364 372 (27.3) | 1297 426 (32.8) |
| No before 2h               | 59 5 (8.5) | 73 29 (39.7) | 355 126 (35.5) | 401 149 (37.2) |
| after 2h                   | 33 2 (6.1) | 33 15 (45.5) | 271 97 (35.8) | 300 124 (41.3) |
| Somnolence                 | 1704 260 (15.3) | 633 169 (26.7) | 1601 455 (28.4) | 1563 508 (32.5) |
| No before 2h               | 41 10 (24.4) | 40 15 (37.5) | 118 43 (36.4) | 135 67 (49.6) |
| after 2h                   | 27 6 (22.2) | 26 10 (38.5) | 85 32 (37.6) | 101 51 (50.5) |
| Paresthesia                | 1714 266 (15.5) | 656 177 (27.0) | 1616 464 (28.7) | 1550 517 (33.4) |
| No before 2h               | 31 4 (12.9) | 17 7 (41.2) | 103 34 (33.0) | 148 58 (39.2) |
| after 2h                   | 16 2 (12.5) | 8 2 (25.0) | 73 26 (35.6) | 115 50 (43.5) |
| Nausea                     | 1705 267 (15.7) | 652 180 (27.6) | 1616 479 (29.2) | 1594 542 (34.0) |
| No before 2h               | 40 3 (7.5) | 21 4 (19.0) | 76 19 (25.0) | 104 33 (31.7) |
| after 2h                   | 20 3 (15.0) | 10 3 (30.0) | 50 15 (30.0) | 70 24 (34.3) |
| Fatigue                    | 1731 270 (15.6) | 654 179 (27.4) | 1633 472 (28.9) | 1603 534 (33.3) |
| No before 2h               | 14 0 (0.0) | 19 5 (26.3) | 86 26 (30.2) | 95 41 (43.2) |
| after 2h                   | 6 0 (0.0) | 9 2 (22.2) | 56 16 (28.6) | 63 27 (42.9) |
| * p<0.05, ** p<0.01, *** p<0.001
Abbreviations: CI = confidence interval; CTEAE = common treatment-emergent adverse event; h = hour; L = lasmiditan; N = number of participants in the treatment group; N’ = number of participants experiencing the TEAE category; n = number of participants experiencing the TEAE category and pain freedom; NA = not applicable
| Participants with | Placebo N=1760 | L50 mg N=679 | L100 mg N=1742 | L200 mg N=1708 | Odds Ratio |
|------------------|---------------|-------------|----------------|----------------|------------|
|                   | N' n (%)      | N' n (%)    | N' n (%)       | N' n (%)       | (95% CI)   |
| ≥1 CTEAE         |               |             |               |               |            |
| No               | 1591 309 (19.4%) | 529 159 (30.1%) | 1125 332 (29.5%) | 992 294 (29.6%) | 0.9 (0.7, 1.2) |
| Yes             | 169 24 (14.2%) | 150 46 (30.7%) | 617 161 (26.1%) | 716 217 (30.3%) | 1.1 (0.9, 1.4) |
| before 2h        | 96 14 (14.6%) | 79 26 (32.9%) | 449 114 (25.4%) | 528 164 (31.1%) | 0.7 (0.4, 1.2) |
| after 2h         | 45 6 (13.3%) | 24 5 (20.8%) | 70 21 (30.0%) | 84 17 (20.2%) | 1.9 (1.0, 3.4)* |
| Dizziness        |               |             |               |               |            |
| No               | 1698 327 (19.3%) | 606 178 (29.4%) | 1380 397 (28.8%) | 1306 395 (30.2%) | 1.0 (0.7, 1.3) |
| Yes             | 62 6 (9.7%) | 73 27 (37.0%) | 362 96 (26.5%) | 402 116 (28.9%) | 1.0 (0.8, 1.3) |
| before 2h        | 35 2 (5.7%) | 33 17 (51.5%) | 274 68 (24.8%) | 301 90 (29.9%) | 0.7 (0.3, 1.7) |
| after 2h         | 15 2 (13.3%) | 14 3 (21.4%) | 31 10 (32.3%) | 43 10 (23.3%) | 1.4 (0.6, 3.0) |
| Somnolence       |               |             |               |               |            |
| No               | 1718 323 (18.8%) | 639 191 (29.9%) | 1623 459 (28.3%) | 1571 458 (29.2%) | 1.1 (0.7, 1.7) |
| Yes             | 42 10 (23.8%) | 40 14 (35.0%) | 119 34 (28.6%) | 137 53 (38.7%) | 1.7 (1.1, 2.4)* |
| before 2h        | 28 7 (25.0%) | 26 9 (34.6%) | 84 24 (28.6%) | 102 38 (37.3%) | 0.8 (0.3, 2.5) |
| after 2h         | 8 1 (12.5%) | 6 1 (16.7%) | 20 6 (30.0%) | 23 8 (34.8%) | 1.4 (0.5, 3.8) |
| Paresthesia      |               |             |               |               |            |
| No               | 1729 329 (19.0%) | 662 198 (29.9%) | 1639 467 (25.8%) | 1556 458 (29.4%) | 1.3 (0.9, 1.9) |
| Yes             | 31 4 (12.9%) | 17 7 (41.2%) | 103 26 (25.2%) | 152 53 (34.9%) | 1.3 (0.9, 1.9) |
| before 2h        | 16 2 (12.5%) | 8 1 (12.5%) | 73 19 (26.0%) | 119 46 (38.7%) | 0.8 (0.1, 4.1) |
| after 2h         | 11 2 (18.2%) | 2 1 (50.0%) | 11 3 (27.3%) | 13 2 (15.4%) | 5.3 (0.9, 32.4) |
| Nausea           |               |             |               |               |            |
| No               | 1719 330 (19.2%) | 658 202 (30.7%) | 1665 485 (29.1%) | 1604 487 (30.4%) | 0.3 (0.2, 0.7)** |
| Yes             | 41 3 (7.3%) | 21 3 (14.3%) | 77 8 (10.4%) | 104 24 (23.1%) | 1.0 (0.6, 1.6) |
| before 2h        | 20 2 (10.0%) | 10 2 (20.0%) | 50 5 (10.0%) | 71 14 (19.7%) | 1.4 (0.3, 6.1) |
| after 2h         | 16 0 (0.0%) | NA 5 (0.0%) | 12 2 (16.7%) | 19 3 (15.8%) | 1.4 (0.3, 6.1) |
| Fatigue          |               |             |               |               |            |
| No               | 1746 333 (19.1%) | 660 202 (30.6%) | 1655 475 (28.7%) | 1615 480 (29.7%) | 0.7 (0.4, 1.2) |
| Yes             | 14 0 (0.0%) | 19 3 (15.8%) | 87 18 (20.7%) | 93 31 (33.3%) | 1.3 (0.8, 2.1) |
| before 2h        | 7 0 (0.0%) | NA 9 (0.0%) | 57 11 (19.3%) | 62 18 (29.0%) | 0.9 (0.2, 4.6) |
| after 2h         | 5 0 (0.0%) | NA 3 (33.3%) | 12 3 (25.0%) | 12 2 (16.7%) | 1.8 (0.3, 9.9) |

* p<0.05, ** p<0.01, *** p<0.001
Abbreviations: CI = confidence interval; CTEAE = common treatment-emergent adverse event; h = hour; L = lasmiditan; N = number of participants in each treatment group; N’ = number of participants experiencing the CTEAE category; n = number of participants experiencing the CTEAE category and disability freedom
Supplemental Table 7. Improved PGIC in participants with a CTEAE or no CTEAE

| Participants with CTEAE | Placebo N=1829 | L50 mg N=685 | L100 mg N=1800 | L200 mg N=1766 | Odds Ratio (95% CI) |
|-------------------------|----------------|--------------|----------------|----------------|-------------------|
| ≥1 CTEAE               |                |              |                |                |                   |
| No                      | 1652           | 353 (21.4%)  | 535            | 192 (35.9%)    | 1.1 (0.7, 1.6)    |
|            | 177            | 38 (21.5%)   | 150            | 58 (38.7%)     | 1.1 (0.7, 1.6)    |
| before 2h               | 99             | 26 (26.3%)   | 79             | 29 (36.7%)     | 1.2 (0.5, 3.3)    |
| after 2h                | 48             | 6 (12.5%)    | 24             | 8 (33.3%)      | 1.7 (0.6, 4.7)    |
| Dizziness               |                |              |                |                |                   |
| No                      | 1765           | 380 (21.5%)  | 612            | 219 (35.8%)    | 1.3 (0.8, 2.2)    |
|            | 64             | 11 (17.2%)   | 73             | 31 (42.5%)     | 0.8 (0.4, 1.6)    |
| before 2h               | 36             | 6 (16.7%)    | 33             | 15 (45.5%)     | 1.0 (0.2, 5.3)    |
| after 2h                | 16             | 2 (12.5%)    | 14             | 6 (42.9%)      | 1.0 (0.2, 5.3)    |
| Somnolence              |                |              |                |                |                   |
| No                      | 1785           | 373 (20.9%)  | 645            | 233 (36.1%)    | 1.2 (0.6, 2.4)    |
|            | 44             | 18 (40.9%)   | 40             | 17 (42.5%)     | 0.8 (0.4, 1.6)    |
| before 2h               | 29             | 14 (48.3%)   | 26             | 10 (38.5%)     | 1.2 (0.2, 8.1)    |
| after 2h                | 9              | 2 (22.2%)    | 6              | 2 (33.3%)      | 1.6 (0.3, 9.6)    |
| Paresthesia             |                |              |                |                |                   |
| No                      | 1798           | 382 (21.2%)  | 668            | 242 (36.2%)    | 1.3 (0.5, 3.4)    |
|            | 31             | 9 (29.0%)    | 17             | 8 (41.1%)      | 1.7 (0.7, 3.8)    |
| before 2h               | 16             | 6 (37.5%)    | 8              | 3 (37.5%)      | 2.3 (0.2, 25.8)   |
| after 2h                | 11             | 2 (18.2%)    | 2              | 0 (0.0%)       | NA                |
| Nausea                  |                |              |                |                |                   |
| No                      | 1787           | 385 (21.5%)  | 664            | 247 (37.2%)    | 0.3 (0.1, 0.9)*   |
|            | 42             | 6 (14.3%)    | 21             | 3 (14.3%)      | 0.7 (0.3, 1.8)    |
| before 2h               | 20             | 5 (25.0%)    | 10             | 2 (20.0%)      | NA*               |
| after 2h                | 16             | 0 (0.0%)     | 5              | 0 (0.0%)       | NA*               |
| Fatigue                 |                |              |                |                |                   |
| No                      | 1812           | 391 (21.6%)  | 666            | 245 (36.8%)    | 0.7 (0.2, 1.9)    |
|            | 17             | 0 (0.0%)     | 19             | 5 (26.3%)      | 0.0 (-, -)        |
| before 2h               | 8              | 0 (0.0%)     | 9              | 2 (22.2%)      | 1.3 (0.1, 26.6)   |
| after 2h                | 6              | 0 (0.0%)     | 3              | 1 (33.3%)      | NA                |

* p<0.05, ** p<0.01, *** p<0.001
Abbreviations: CI = confidence interval; CTEAE = common treatment-emergent adverse event; h = hour; L = lasmiditan; N = number of participants in each treatment group; N’ = number of participants experiencing the CTEAE category; n = number of participants experiencing the CTEAE category and PGIC; PGIC = patient global impression of change